# Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

> **NCT07555938** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 380 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cevostamab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab
- **DRUG:** Elotuzumab
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT07555938
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-06-29
- **Final completion:** 2032-12-31
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07555938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07555938, "Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07555938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*